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Mutations in the mitofusin 2 (MFN2) gene, which encodes a mitochondrial GTPase mitofusin protein, have
recently been reported to cause both Charcot–Marie–Tooth 2A (CMT2A) and hereditary motor and sensory
neuropathy VI (HMSN VI). It is well known that HMSN VI is an axonal CMT neuropathy with optic atrophy.
However, the differences between CMT2A and HMSN VI with MFN2 mutations remained to be clarified.
Therefore, we studied the phenotypic characteristics of CMT patients with MFN2 mutations. Mutations in
MFN2 were screened in 62 unrelated axonal CMT neuropathy families. We calculated CMT neuropathy scores
(CMTNSs) and functional disability scales (FDSs) to quantify disease severity. Twenty-one patients with the
MFN2mutations were studied by brain MRI. Ten pathogenic mutations were identified in 26 patients from 15
families (24.2%). Six of these mutations had not been reported, and de novo mutations were observed in five
families (33.3%). The electrophysiological patterns of affected individuals with theMFN2mutations were typical
of axonal CMT; however, the clinical and electrophysiological characteristics were markedly different in early
(<10 years) and late disease-onset (>10 years) groups. All patients with an early onset had severe CMTNS (>21)
and FDS (6 or 7), whereas most patients with late onset had mild CMTNS (<10) and FDS (<3). We identified
two HMSNVI families with the R364Wmutation in the early onset group; however, two other families with the
same mutation did not have optic atrophy. In addition, two early onset families with R94W mutations, pre-
viously reported for HMSN VI, did not have visual impairment. Interestingly, eight patients had periventricular
and subcortical hyperintense lesions by brain MRI. In the late-onset group, three patients had sensorineural
hearing loss and two had bilateral extensor plantar responses. We found that MFN2 mutations are the major
cause of axonal CMT neuropathy, and that they are associated with variable CNS involvements. Phenotypes
were significantly different in the early and late disease-onset groups. Our findings suggest that HMSNVImight
be a variant of the early onset severe CMT2A phenotype.
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Abbreviations: CMAP = compound muscle action potential; CMT = Charcot–Marie–Tooth; CMTNS = CMT
neuropathy score; FDS = functional disability scale; FLAIR = fluid-attenuated inversion recovery; HMSN = hereditary
motor and sensory neuropathy; MCV = motor nerve conduction velocity; MFN2 = mitofusin 2; MNF = myelinated nerve
fibre; MRC = Medical Research Council; PCR = polymerase chain reaction; SCV = sensory nerve conduction velocity;
SNAP = sensory nerve action potential; SNHL = sensorineural hearing loss; TLIs = terminal latency indices; VEP = visual
evoked potential
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Introduction
Charcot–Marie–Tooth (CMT) disease is a genetically and
clinically heterogeneous disorder, and many CMT-causative
genes have been identified (Shy et al., 2004). CMT is fre-
quently classified as type 1, the demyelinating form (CMT1),
or type 2, the axonal form (CMT2). The primary defect
in CMT2 patients is neuronal, and CMT2 patients have
slightly reduced (>38 m/s) or even normal nerve conduction
velocities (NCVs) (Pareyson et al., 2004).
CMT2 has been divided into many subtypes by linkage
analysis as follows: CMT2A (1p35–p36), 2B (3q21), 2D
(7p15), 2E (8p21), 2F (7q11.23), 2G (12q12–q13.3), 2I
(1q22), 2K (8q13–q21.1) and 2L (12q24). Several genes
have been reported to be associated with CMT2 loci, namely,
kinesin family member 1B-b (KIF1B: MIM no. 605995) in
CMT2A (Zhao et al., 2001), RAB7 (MIM no. 602298) in
CMT2B (Verhoeven et al., 2003), GARS (MIM no.
600287) in CMT2D (Antonellis et al., 2003), NEFL (MIM
no. 162280) in CMT2E (Mersiyanova et al., 2000; Choi et al.,
2004), HSPB1 (MIM no. 602195) in CMT2F (Evgrafov et al.,
2004), MPZ (MIM no. 159440) in CMT2I (Boerkoel et al.,
2002) and HSPB8 (MIM no. 608014) in CMT2L (Tang et al.,
2005).
Following the mapping of CMT2A to the short arm of
chromosome 1, 1p35–p36, a missense mutation was detected
in KIF1B in a Japanese CMT2A family (Zhao et al., 2001).
However, no other mutation has been identified in KIF1B,
and, thus, it is believed that another gene is involved (Muglia
et al., 2001; Bissar-Tadmouri et al., 2004). By linkage analysis
and screening genes linked to the CMT2A locus, Zu¨chner
et al. (2004) first identified several mutations in the mito-
fusin 2 (MFN2) gene. Subsequently, additional MFN2 muta-
tions were reported in CMT2A patients (Kijima et al., 2005;
Lawson et al., 2005). Thus, today, mutations in MFN2 are
considered to provide the genetic basis of the CMT2A phe-
notype. MFN2 encodes an outer mitochondrial membrane
protein, which has important roles in the regulation of the
fusion of mitochondria in cooperation with the Mfn1 iso-
form (Rojo et al., 2002; Chen et al., 2003; Koshiba et al.,
2004). Mitochondrial fusion is essential for various biological
functions in eukaryotic cells (Chen et al., 2005). It has also
been suggested that MFN2 may be associated with the main-
tenance of mitochondrial membrane potentials (Honda et al.,
2005). Moreover, MFN2-deficient mice die in mid-gestation
and display fragmented mitochondria (Chen et al., 2003). In
addition, it is believed, even in a few population-based
studies, that MFN2 mutations are most common in
CMT2 (Szigeti et al., 2006).
Recently, axonal CMT neuropathy with visual impairment
due to optic atrophy designated as hereditary motor and
sensory neuropathy type VI (HMSN VI) was also shown to
be caused by mutations in the MFN2 gene (Zu¨chner et al.,
2006). After the vertical inheritance in HMSN VI from
male to male was first documented by Vizioli (1889),
other patterns of inheritance have been demonstrated,
that is, autosomal dominant with incomplete penetrance
(Voo et al., 2003; Zu¨chner et al., 2006), autosomal recessive
(Schneider and Abeles, 1937; Iwashita et al., 1970), X-linked
recessive (Rosenberg and Chutorian, 1967) and sporadic
(Krauss, 1906). These variable inheritance patterns of
HMSN VI may be due to the incomplete penetrance of
optic atrophy.
Because MFN2 mutation screening studies and examina-
tions of the relationships between genotypes and clinical
phenotypes have only been performed recently in CMT
patients, mutation data in different ethnic groups are limited
(Kijima et al., 2005; Lawson et al., 2005). Therefore, we
screened for MFN2 mutations in 62 unrelated axonal
CMT neuropathy families and identified 10 causative muta-
tions in 15 families. We found that some affected individuals
developed unusually severe phenotypes with an early onset
and others a mild form of axonal neuropathy with a late age
of onset. In addition, we detected two HMSN VI families
with the R364W MFN2 mutation; however, the other
two families with the same mutations did not show optic
atrophy.
Patients and methods
Patients
This study included a total of 218 patients from 62 families with
distinct CMT type 2 phenotypes of Korean origin. Blood samples
were collected from patients diagnosed as having CMT at Ewha
Woman’s University Hospital. The clinical guidelines of the
European CMT consortium were used to diagnose CMT type 2
(De Jonghe et al., 1998). In addition, 200 healthy controls for
sequence variations were recruited from the neurological depart-
ment, after careful clinical and electrophysiological examinations. In
families with de novo mutation, paternity and maternity were con-
firmed in these families by genotyping 15 markers provided in
AmpFLSTR identifier kits (Applied Biosystems, Foster City, CA,
USA). All participants included in this study provided written
informed consent according to the protocol approved by the Ethics
Committee of Ewha Woman’s University Hospital.
MFN2 mutation screening
DNA was extracted from blood samples using a genomic DNA
isolation kit (SolGent, Daejeon, Korea). All exons of MFN2 were
amplified using a standard polymerase chain reaction (PCR)
method. Exons 7–8, 10–11 and 13–14 were amplified together,
whereas the others were amplified separately. The primer sequences
and PCR conditions used are available on request. PCR products
were purified using PCR product purification kits (SolGent,
Daejeon, Korea) and sequenced using an ABI 3100 automatic
sequencer (Applied Biosystems-Hitachi, Tokyo, Japan). Sequence
variations were confirmed by analysing both DNA strands.
Clinical assessment
Clinical information was obtained in a standardized manner and
included assessments of motor and sensory impairments, deep ten-
don reflexes and muscle atrophy. Muscle strengths of flexor and
extensor muscles were assessed manually using the standard Med-
ical Research Council (MRC) scale. In order to determine physical
disability, we used two scales, a functional disability scale (FDS)
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(Birouk et al., 1998) and a CMT neuropathy score (CMTNS)
(Shy et al., 2005). Disease severity was determined for each patient
using a nine-point FDS, which was based on the following criteria:
0 = normal; 1 = normal but with cramps and fatigability; 2 = an
inability to run; 3 = walking difficulty but still possible unaided;
4 = walking with a cane; 5 = walking with crutches; 6 = walking with
a walker; 7 = wheelchair-bound; and 8 = bedridden. In addition, we
determined the recently created CMTNS, based on motor and sen-
sory symptoms, and on pain and vibration, muscle strength and
neurophysiological test results. Moreover, patients were divided
into mild (CMTNS < 10), moderate (CMTNS >11 and <20)
and severe (CMTNS > 21) categories. Sensory impairments were
assessed in terms of the level and severity of pain, temperature,
vibration and position, and pain and vibration sense were com-
pared. Age at onset was determined by asking patients for their ages,
when symptoms, that is, distal muscle weakness, foot deformity or
sensory change, first appeared. Ophthalmological examination,
done in all patients with MFN2 mutations, included best-corrected
visual acuity, colour vision using Ishihara colour plates, pupillary
reflex, automated visual field test, anterior segment and dilated
fundus examination.
Electrophysiological study
Motor and sensory conduction velocities of median, ulnar, peroneal,
tibial and sural nerves were determined in 26 patients. Recordings
were obtained by standard methods using surface stimulation and
recording electrodes. Motor conduction velocities (MCVs) of the
median and ulnar nerves were determined by stimulating at the
elbow and wrist while recording compound muscle action potentials
(CMAPs) over the abductor pollicis brevis and abductor digiti quinti,
respectively. In the same way, the MCVs of peroneal and tibial nerves
were determined by stimulating at the knee and ankle, while record-
ing CMAPs over the extensor digitorum brevis and abductor hallucis,
respectively. CMAP amplitudes were measured from positive peak to
negative peak values. Sensory conduction velocities (SCVs) were
obtained over a finger-wrist segment from the median and ulnar
nerves by orthodromic scoring and were also recorded for sural
nerves. Sensory nerve action potential (SNAP) amplitudes were mea-
sured from positive peaks to negative peaks. Terminal latency indices
(TLIs) were calculated for median nerves [TLI = terminal distance
(mm)/MCV (m/s) · distal motor latency (ms)].
MRI study
Twenty-one individuals withMFN2mutations were evaluated using
a 1.5-T system (Siemens Vision; Siemens, Erlangen, Germany).
Whole brains were scanned using a slice thickness of 7 mm and
a 2-mm interslice gap, to produce 16 axial images. The imaging
protocol consisted of T2-weighted spin echo [repetition time
(TR)/echo time (TE) = 4700/120 ms], T1-weighted spin echo
(TR/TE = 550/12 ms) and fluid-attenuated inversion recovery
(FLAIR) (TR/TE = 9000/119 ms, inversion time 2609 ms) images.
Histopathological study
Pathological examinations of affected individuals included the light
and electron microscopic analyses of a sural nerve. One sural
nerve fragment was fixed in 10% formalin, embedded in paraffin
and stained with haematoxylin–eosin (H–E). Another fragment
was immediately fixed by immersion in 5% buffered glutaraldehyde
and post-fixed in 1% osmium tetroxide. Epon-embedded semi-thin
and ultra-thin sections were prepared for light and ultra-structural
examinations. In addition, a muscle biopsy was taken from the gas-
trocnemius under local anaesthesia. Cross-sections of biopsy tissue
were stained with H–E, modified Gomori-trichrome and oxidative
enzymes (NADH-TR, succinate dehydrogenase). Another biopsy
fragment was examined by electron microscopy.
Statistical analysis
Percentages and means were compared using the x2-test and the
Student’s t-test, respectively. Correlation studies were performed
using Spearman’s correlation coefficient (r), and strong correlations
were considered significant when r-values were >0.7 and P-values
were <0.05. Statistical significance was accepted for P-values exceed-
ing 0.05. Statistical analyses were performed using SPSS for
Windows, Ver. 11.0 (SPSS Inc., Chicago, IL, USA).
Results
Identification of causative mutations
Mutation screening of MFN2 in 62 unrelated CMT2 families
identified ten causative missense mutations in 15 families
(24.2%). Details of the mutations are listed in Table 1.
Most mutations were located within or close to the GTPase
domain. Six mutations [c.275T!C (L92P), c.380G!A
(G127D), c.494A!G (H165R), c.787T!C (S263P),
c.1085C!T (T362M) and c.1127T!C (M376T)] had not
been reported previously, and were not detected in the 400
control chromosomes (Fig. 1A). Amino acid sequences are
highly conserved in different species at most mutation sites
(Fig. 1B). In the present study, CMT2A families with MFN2
mutations showed an autosomal dominant inheritance, even
though there were de novomutations. Five de novo mutations
were proved in 5 families of the 15 CMT2A families (33.3%),
which is a high rate.
The c.275T!C (L92P) de novo mutation at exon 4 was
found in a patient with a severe CMT2 phenotype (FC34).
This mutation was only detected in the proband (III-2), who
was the only affected member of his family (Fig. 2A). The
c.280C!T (R94W) autosomal dominant mutation at exon 4
was detected in severely affected individuals of two CMT2
families. This mutation was transmitted from father (possi-
ble affected) to son in Family FC25 (Fig. 2B) and from
mother to son in Family FC113 (Fig. 2C), respectively. Muta-
tions at the 94th codon have been previously reported in
several families (Zu¨chner et al., 2004; Kijima et al., 2005).
Two de novo mutations at exon 5, c.314C!T (T105M) and
c.380G!A (G127D), were identified in CMT2 families with
a mild phenotype, FC135 (Fig. 2D) and FC48 (Fig. 2E),
respectively. The T105M mutation has been previously
reported in two CMT2 families (Zu¨chner et al., 2004;
Lawson et al., 2005). The c.494A!G (H165R) mutation
at exon 6 was detected in two CMT2 families with a mild
phenotype, FC81 (Fig. 2F) and FC111 (Fig. 2G). This muta-
tion co-segregated to affected members in both pedigrees in
an autosomal dominant mode. The exon 8 c.787T!C
(S263P) mutation was identified in a mild CMT2 family
(FC52) and had been transmitted from mother to son
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(Fig. 2H), and c.839G!A (R280H), an autosomal dominant
mutation at exon 9, was also identified in a mild CMT2
family, FC169 (Fig. 2I). The R280H mutation has been pre-
viously reported in a CMT2 family (Zu¨chner et al., 2004). A
novel c.1085C!T (T362M) mutation was observed in a late-
onset CMT2 family with a mild phenotype (FC188). The
proband (II-2) had received the mutation from her mother
(I-2), who showed very mild phenotype (Fig. 2J). Four
families with a severe phenotype were found to possess
c.1090C!T (R364W) at exon 11. In the FC1 pedigree
(Fig. 2K), the proband (III-1) and her twin sister (III-2)
had received the mutation from their mother (II-3),
Table 1 Mutations found in the MFN2 gene in Korean pedigrees
Exon Domain Nucleotide
change
Amino acid
change
Index family Inheritance Phenotype Reference
Exon 4 c.275T!C p.L92P FC34 De novo Early onset, severe This study
Exon 4 c.280C!T p.R94W FC25
FC113
AD
AD
Early onset, severe
Early onset, severe
Zu¨chner et al., 2004, 2006;
Kijima et al., 2005
Exon 5 GTPase c.314C!T p.T105M FC135 De novo Late onset, mild Zu¨chner et al., 2004;
Lawson et al., 2005
Exon 5 GTPase c.380G!A p.G127D FC48 De novo Late onset, mild This study
Exon 6 GTPase c.494A!G p.H165R FC81
FC111
AD
AD
Late onset, mild
Late onset, mild
This study
Exon 8 c.787T!C p.S263P FC52 AD Late onset, mild This study
Exon 9 c.839G!A p.R280H FC169 AD Late onset, mild Zu¨chner et al., 2004
Exon 11 c.1085C!T p.T362M FC188 AD Late onset, mild This study
Exon 11 c.1090C!T p.R364W FC1 AD (De novo) Early onset, severe Zu¨chner et al., 2006
FC6 AD Early onset, severe
FC55 De novo Early onset, severe
FC87 AD Early onset, severe
Exon 11 c.1127T!C p.M376T FC70 AD Late onset, mild This study
Nucleotide numbering: the first nt ‘A’ of the ATG translation start codon is designated +1.
Reference sequence accession number of MFN2 is NM 014874.
AD = autosomal dominant inheritance.
Fig. 1 MFN2 mutations and their conservation in species. (A) Chromatograms of six novel mutations. Exons were amplified by standard
PCR and sequenced using an ABI 3100 automatic sequencer (Applied Biosystems-Hitachi, Tokyo, Japan). (B) Conservation of amino acids at
mutation sites in different species. Mutation sites are indicated by arrows.
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but II-3 was a de novo case. FC6 (Fig. 2L) and FC87 (Fig. 2N)
showed autosomal dominant inheritance (mother to son),
whereas FC55 (Fig. 2M) showed a de novo mutation. The
c.1127T!C (M376T) autosomal dominant mutation at exon
11 was identified in mild patients in a CMT2 pedigree (FC70;
Fig. 2O). This mutation had been transmitted from mother
(I-2) to the proband (II-5) and her brother (II-4).
We also found several polymorphic variants in the exon
region: c.–212T!C (50-UTR, exon 1), c.150C!A (I150I),
c.165C!T (T55T), c.408A!T (V136V), c.1569C!T
(S523S) and c.2332A!G (30-UTR at exon 19). These var-
iants were also observed in controls, but no amino acid
substitutions were involved; thus, they were not regarded
as causative mutations. Some polymorphic sites
(c.150C!A, c.165C!T, c.408A!T and c.1569C!T) have
been reported previously (Kijima et al., 2005). A mutation at
intron 5 near the 50-splicing site, c.474+4A!G, was also
detected in two CMT2 families. However, this mutation
did not co-segregate to affected individuals and was also
found in controls at a frequency of 0.015, and, thus, was
not considered a causative mutation.
Clinical findings
The clinical features of the 26 patients (11 males, 15 females)
from the 15 families are shown in Table 2. Muscle weakness
and atrophy started and predominated in the distal portions
of legs and were noted to a lesser extent distally in upper
limbs. Paresis in the distal regions of lower limbs varied from
asymptomatic or mild weakness to the complete paralysis of
distal muscle groups.
Age at onset was earlier than 10 years (early onset group)
in five males and seven females and occurred later (late-onset
group) in six males and eight females. Mean age at onset
was 3.9 6 3.0 years (range: 1–9 years) in the early onset
group and 23.9 6 13.0 years (range: 10–50 years) in
Fig. 2 Pedigrees of CMT2A families with MFN2 mutation. The available DNA samples are indicated by asterisks (*). The open symbols
represent unaffected males (open squares) and unaffected females (open circles), and filled symbols represent affected males (closed
squares) and affected females (closed circles). The half-filled symbol indicates a possible affected male. The arrows indicate probands.
(A) FC34 with L92P, (B) FC25 with R94W, (C) FC113 with R94W, (D) FC135 with T105M, (E) FC48 with G127D, (F) FC81 with H165R,
(G) FC111 with H165R, (H) FC52 with S263P, (I) FC169 with R280H, (J) FC188 with T362M, (K) FC1 with R364W, (L) FC6 with R364W,
(M) FC55 with R364W, (N) FC87 with R364W and (O) FC70 with M376T.
Early and late-onset MFN2 mutations Brain (2006), 129, 2103–2118 2107
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on June 17, 2014
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
T
a
b
le
2
C
lin
ic
al
fe
at
u
re
s
in
2
6
C
M
T
p
at
ie
n
ts
fr
o
m
1
5
fa
m
ili
es
w
it
h
M
FN
2
m
u
ta
ti
o
n
s
P
at
ie
n
ts
Se
x
A
ge
at
ex
am
(y
ea
rs
)
A
ge
at
o
n
se
t
(y
ea
rs
)
D
is
ea
se
d
u
ra
ti
o
n
(y
ea
rs
)
FD
S
C
M
T
N
S
M
u
sc
le
w
ea
kn
es
sa
M
u
sc
le
at
ro
p
h
yb
Se
n
so
ry
lo
ss
c
D
T
R
d
A
d
d
it
io
n
al
sy
m
p
to
m
s
P
at
h
o
lo
gi
ca
l
fin
d
in
gs
U
/E
L/
E
U
/E
L/
E
U
/E
L/
E
E
ar
ly
ag
e
at
o
n
se
t
(<
1
0
ye
ar
s)
FC
1
(I
I-
3
)
F
3
5
8
2
7
7
3
6
+
+
+
+
+
Se
ve
re
(U
<
L)
P
=
V
P
=
V
A
A
Sc
o
lio
si
s,
co
n
tr
ac
tu
re
o
p
ti
c
at
ro
p
h
y
Su
ra
l
n
er
ve
,
ax
o
n
al
,
p
se
u
d
o
-o
n
io
n
b
u
lb
FC
1
(I
II
-1
)
F
1
2
1
1
1
7
3
6
+
+
+
+
+
Se
ve
re
(U
<
L)
P
=
V
P
=
V
A
A
Sc
o
lio
si
s,
co
n
tr
ac
tu
re
N
D
e
FC
1
(I
II
-2
)
F
1
2
1
1
1
7
3
6
+
+
+
+
+
Se
ve
re
(U
<
L)
P
=
V
P
<
V
A
A
Sc
o
lio
si
s,
co
n
tr
ac
tu
re
N
D
FC
6
(I
I-
6
)
F
3
3
5
2
8
7
3
6
+
+
+
+
+
Se
ve
re
(U
<
L)
P
<
V
P
<
V
A
A
Sc
o
lio
si
s,
co
n
tr
ac
tu
re
h
o
ar
se
n
es
s,
o
p
ti
c
at
ro
p
h
y
Su
ra
l
n
er
ve
,
ax
o
n
al
FC
6
(I
II
-1
)
M
1
4
2
1
2
7
3
4
+
+
+
+
+
Se
ve
re
(U
<
L)
P
<
V
P
<
V
A
A
Sc
o
lio
si
s,
co
n
tr
ac
tu
re
,
o
p
ti
c
at
ro
p
h
y
N
D
FC
2
5
(I
I-
2
)
M
2
8
9
1
9
6
2
2
+
+
+
+
+
Se
ve
re
(U
<
L)
P
=
V
P
=
V
A
A
–
N
D
FC
3
4
(I
II
-2
)
M
1
3
1
1
2
6
3
1
+
+
+
+
+
Se
ve
re
(U
<
L)
P
=
V
P
<
V
A
A
Sc
o
lio
si
s
Su
ra
l
n
er
ve
,
ax
o
n
al
FC
5
5
(I
I-
2
)
F
6
3
3
6
3
1
+
+
+
+
+
Se
ve
re
(U
<
L)
P
=
V
P
<
V
A
A
Sc
o
lio
si
s
N
D
FC
8
7
(I
I-
3
)
F
2
2
4
1
8
7
3
6
+
+
+
+
+
Se
ve
re
(U
<
L)
P
<
V
P
<
V
A
A
Sc
o
lio
si
s,
co
n
tr
ac
tu
re
Su
ra
l
n
er
ve
,
ax
o
n
al
FC
8
7
(I
II
-1
)
M
3
1
2
6
2
8
+
+
+
+
+
Se
ve
re
(U
<
L)
N
D
N
D
A
A
–
N
D
FC
1
1
3
(I
I-
5
)
F
3
7
8
2
9
7
3
3
+
+
+
+
+
Se
ve
re
(U
<
L)
P
<
V
P
<
V
A
A
Sc
o
lio
si
s,
co
n
tr
ac
tu
re
Su
ra
l
n
er
ve
,
ax
o
n
al
FC
1
1
3
(I
II
-1
)
M
6
4
2
6
2
2
+
+
+
+
Se
ve
re
(U
<
L)
P
<
V
P
<
V
A
A
Sc
o
lio
si
s
N
D
La
te
ag
e
at
o
n
se
t
(>
1
0
ye
ar
s)
FC
4
8
(I
I-
3
)
M
2
6
1
6
1
0
2
4

+
N
o
n
l
P
>
V
N
I
E
x
te
n
so
r
p
la
n
ta
r
re
sp
o
n
se
s
N
D
FC
5
2
(I
I-
1
)
M
1
4
1
2
2
1
5

+
M
ild
(L
)
P
=
V
P
=
V
D
D
–
N
D
FC
7
0
(I
I-
5
)
F
5
3
3
9
1
4
2
1
0
+
+
+
M
ild
(U
<
L)
P
=
V
P
=
V
D
A
P
ai
n
N
D
FC
8
1
(I
I-
5
)
F
6
4
5
0
1
4
1
5


N
o
P
=
V
P
=
V
N
D
T
re
m
o
r,
SN
H
L
Su
ra
l
n
er
ve
,
ax
o
n
al
FC
8
1
(I
II
-3
)
M
3
5
1
0
2
5
3
1
5
+
+
+
M
ild
(U
<
L)
P
=
V
P
>
V
N
A
T
re
m
o
r,
SN
H
L,
h
o
ar
se
n
es
s
N
D
FC
1
1
1
(I
II
-2
)
M
2
0
1
4
6
1
5

+
N
o
P
=
V
P
=
V
N
D
–
N
D
FC
1
3
5
(I
II
-4
)
F
1
2
1
1
1
2
6
+
+
+
M
ild
(L
)
P
=
V
P
=
V
D
A
T
re
m
o
r
G
as
tr
o
cn
em
iu
s
m
u
sc
le
,
n
o
R
R
F
FC
1
6
9
(I
II
-4
)
F
4
5
2
3
2
2
1
6
+
+
+
M
ild
(L
)
P
>
V
P
>
V
N
D
P
ai
n
,
tr
em
o
r,
d
ys
ar
th
ri
a,
m
ig
ra
in
e
N
D
FC
1
6
9
(I
II
-6
)
F
4
0
3
4
6
1
7

+
N
o
P
=
V
P
=
V
N
D
T
re
m
o
r
N
D
FC
1
6
9
(I
II
-7
)
M
3
7
2
7
1
0
0
2

+
N
o
n
l
n
l
N
I
E
x
te
n
so
r
p
la
n
ta
r
re
sp
o
n
se
s
N
D
FC
1
6
9
(I
II
-8
)
F
5
2
2
5
2
7
1
8
+
+
N
o
P
=
V
P
=
V
N
D
P
ai
n
,
tr
em
o
r,
d
ys
ar
th
ri
a,
m
ig
ra
in
e
N
D
FC
1
6
9
(I
II
-1
2
)
M
3
8
2
0
1
8
2
9

+
M
ild
(L
)
n
l
P
=
V
N
N
P
ai
n
,
tr
em
o
r,
SN
H
L
N
D
FC
1
6
9
(I
V
-4
)
F
1
4
1
1
3
2
1
0
+
+
+
M
ild
(L
)
P
=
V
P
=
V
N
D
P
ai
n
,
tr
em
o
r
N
D
FC
1
8
8
(I
I-
2
)
F
4
9
4
2
7
1
7

+
M
ild
(L
)
P
=
V
P
=
V
N
D
T
ra
n
si
en
t
se
n
so
ry
lo
ss
Su
ra
l
n
er
ve
,
ax
o
n
al
a M
u
sc
le
w
ea
kn
es
s
in
lo
w
er
lim
b
s:
+
=
an
kl
e
d
o
rs
ifl
ex
io
n
4
/5
o
n
M
R
C
sc
al
e;
+
+
=
an
kl
e
d
o
rs
ifl
ex
io
n
<
4
/5
o
n
M
R
C
sc
al
e;
+
+
+
=
p
ro
x
im
al
w
ea
kn
es
s
an
d
w
h
ee
lc
h
ai
r-
d
ep
en
d
en
t.
M
u
sc
le
w
ea
kn
es
s
in
u
p
p
er
lim
b
s:
+
=
in
tr
in
si
c
h
an
d
w
ea
kn
es
s
4
/5
o
n
M
R
C
sc
al
e;
+
+
=
in
tr
in
si
c
h
an
d
w
ea
kn
es
s
<
4
/5
o
n
M
R
C
sc
al
e;

=
n
o
sy
m
p
to
m
s.
b
M
u
sc
le
at
ro
p
h
y:
U
<
L
=
lo
w
er
lim
b
p
re
d
o
m
in
an
t
m
u
sc
le
at
ro
p
h
y;
L
=
o
n
ly
lo
w
er
lim
b
m
u
sc
le
at
ro
p
h
y.
c S
en
so
ry
lo
ss
:
P
=
p
ai
n
se
n
se
;
V
=
vi
b
ra
ti
o
n
se
n
se
;
n
l
=
n
o
rm
al
se
n
se
.
d
D
ee
p
te
n
d
o
n
re
fle
x
es
:
N
=
n
o
rm
al
;
D
=
d
im
in
is
h
ed
;
A
=
ab
se
n
t.
e
N
D
=
n
o
t
d
o
n
e.
2108 Brain (2006), 129, 2103–2118 K. W. Chung et al.
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on June 17, 2014
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
late-onset group (P < 0.001). Disease duration at the time of
examination was 14.5 6 9.8 years in the early onset group
and 11.8 6 8.5 years in the late-onset group, which was not
significantly different. Clinical findings confirmed that
patients in the early onset group were more severely affected
than those in the late-onset group, and this was significant for
several items, that is, severity of muscle weakness (P < 0.01),
frequency of upper and lower limb areflexia (P < 0.01) and the
presence of flat feet deformities (P < 0.01). Length-dependent
sensory loss was found in 24 patients (92.3%). Vibration sense
was reduced to a greater extent than pain in 8 of the 12 patients
in the early onset group (66.7%). In the late-onset group, pain
sense was reduced to a greater extent than vibration in 3 of 14
patients (21.4%), whilst in 10 patients (71.4%) those were
reduced to a similar extent.
Functional disability was severe in patients with an early
onset, but mild in patients with a late onset. Mean FDS was
6.6 6 0.5 in the early onset group and 1.4 6 0.8 in late-onset
group (P < 0.001). CMTNS was 31.8 6 5.2 in the early
onset group and 7.1 6 3.2 in the late-onset group, which
was significantly different (P < 0.001). High FDSs (score = 6
or 7) were found only in the early onset group; however,
the late-onset group members showed low FDSs (score < 3).
All 12 patients in the early onset group were in the severe
(CMTNS > 21) category. Except for one patient (III-3 in
Family FC81; CMTNS = 15), who was in moderate
category, 13 of the 14 late-onset patients were in mild
(CNTNS < 10) category. CMTNSs and FDSs showed a
bimodal distribution in patients with MFN2 mutations
(Fig. 3A and B).
Foot deformities were found in all patients. Pes cavus with
flattening was more frequent in the early onset group, and,
similarly, high arched foot deformities were more frequent in
the late-onset group. Associated signs differed in the early
and late-onset groups. Scoliosis (38.5%) and knee joint con-
tracture (26.9%) was found only in patients with an early
onset; however, postural hand tremor (30.8%), pain (19.2%)
and sensorineural hearing loss (SNHL) (11.5%) were
demonstrated by patients with a late onset. In addition,
two affected males had bilateral extensor plantar responses
with no explanation other than CMT.
Electrophysiological findings
Neurophysiological studies were carried out on 26 affected
individuals (11 males and 15 females). MCVs of median,
ulnar, peroneal and tibial nerves and SCVs of median,
ulnar and sural nerves are shown in Table 3. Electrophysio-
logical findings also confirmed that patients with an early
onset were more severely affected than those with a late
onset. In the early onset group, the amplitudes of evoked
motor responses were often markedly reduced, and we were
unable to record amplitudes in 8 of the 12 patients (67%). All
patients, except those with absent NCVs, had at least one
motor NCV > 38 m/s. However, in the late-onset group,
NCVs were obtained for all patients, and some motor
Fig. 3 Quantification of disease severity. Patients with MFN2 mutations were divided into two categories by onset age (early onset
< 10 years or late onset > 10 years). (A) Dimorphic phenotypes of patients with MFN2 mutations by CMTNS. (B) The early onset
group was found to be associated with severe functional disability (FDS = 6 or 7) and the late-onset group with asymptomatic to mild
disease forms (FDS < 3).
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NCVs in upper limbs were normal without conduction
block. In a patient (III-2 in Family FC34) with an early
age at onset, we carried out three follow-up nerve conduction
studies over a 10-year period and finally observed the absence
of action potentials in all nerves tested (Table 3). Sensory and
motor amplitudes changed at a much slower rate in patients
with a late onset than in those with an early onset.
The distal and lower limb predominant motor in-
volvement was common in patients with MFN2 mutations.
Therefore, we studied correlations between CMAP and distal
limb muscle strength. The amplitudes of the CMAPs of
median, ulnar and posterior tibial nerves were found to
be significantly correlated with corresponding distal muscle
strengths in MFN2 patients (r = 0.80, P < 0.001; r = 0.79,
Table 3 Electrophysiological data in 26 CMT patients from 15 families with MFN2 mutations
Patient Age at
exam
Motor NCV (m/s) Sensory NCV (m/s)
Median Ulnar Peroneal Tibial Median Ulnar Sural
Early age at onset (<10 years)
FC1 (II-3) 35 NR NR NR NR NR NR NR
FC1 (III-1) 6 NR NR NR NR NR NR NR
12 NR NR NR NR NR NR NR
FC1 (III-2) 6 43.7 (2.8) 17.3 (0.2) NR NR NR NR NR
12 NR NR NR NR NR NR NR
FC6 (II-6) 33 NR NR NR NR NR NR NR
FC6 (III-1) 7 NR NR NR NR NR NR NR
14 NR NR NR NR NR NR NR
FC25 (II-2) 28 40.3 (1.9) 37.3 (2.4) NR NR NR NR NR
FC34 (III-2) 4 47.1 (1.2) 48.3 (1.2) NR NR 39.6 (29.6) 41.4 (24.8) NR
6 40.3 (2.3) 31.1 (0.4) NR NR 36.5 (19.6) 33.7 (18.0) NR
13 NR NR NR NR NR NR NR
FC55 (II-2) 4 47.2 (7.4) 54.5 (13.0) NR NR 22.9 (1.7) 21.7 (1.6) NR
6 44.2 (2.4) 38.2 (2.7) NR NR NR NR NR
FC87 (II-3) 22 NR NR NR NR NR NR NR
FC87 (III-1) 3 38.9 (1.1) 48.9 (1.5) 37.3 (0.3) NR NR NR NR
FC113 (II-5) 37 NR NR NR NR NR NR NR
FC113 (III-1) 6 53.8 (10.3) 45.9 (7.4) NR NR NR NR NR
Late age at onset (>10 years)
FC48 (II-3) 22 54.5 (11.9) 51.9 (16.6) 34.1 (2.2) 35.2 (0.5) 38.1 (10.4) 34.9 (13.1) NR
23 51.1 (12.5) 54.9 (14.1) 36.6 (3.5) 38.2 (0.5) 41.4 (18.4) 45.6 (14.0) NR
26 53.2 (12.5) 58.1 (16.5) 35.2 (4.1) NR 41.4 (8.2) 38.5 (9.2) NR
FC52 (II-1) 14 50.0 (16.5) 55.7 (19.4) NR NR 36.4 (10.0) 36.7 (12.0) NR
FC70 (II-5) 53 41.2 (10.6) 46.2 (9.6) 37.3 (0.7) 34.7 (0.7) NR NR NR
FC81 (II-5) 60 51.8 (11.5) 50.6 (10.6) 31.4 (0.3) 44.2 (0.2) 40.7 (15.2) 41.5 (14.1) 40.3 (2.6)
64 51.5 (9.4) 55.1 (9.2) 33.4 (1.2) NR 38.2 (8.5) 35.0 (11.9) 17.5 (3.4)
FC81 (III-3) 32 46.0 (7.2) 36.4 (2.5) NR NR NR NR NR
35 49.1 (6.5) 38.6 (2.6) NR NR NR NR NR
FC111 (III-2) 19 54.0 (20.1) 51.0 (16.6) 41.0 (3.2) 46.0 (6.7) 32.0 (2.8) 31.0 (0.8) NR
20 53.0 (19.8) 56.0 (19.0) 42.9 (3.9) 44.7 (8.1) 31.8 (4.0) 31.0 (4.7) NR
FC135 (III-4) 12 54.8 (12.9) 58.0 (13.0) NR 25.5 (0.1) 37.5 (9.9) 33.3 (11.2) NR
FC169 (III-4) 45 57.5 (16.0) 60.3 (16.5) 20.5 (0.1) NR 36.4 (13.6) 35.5 (14.2) 23.9 (6.1)
FC169 (III-6) 40 58.0 (13.8) 62.5 (14.3) 32.0 (2.3) 47.3 (5.2) 42.9 (22.7) 43.1 (23.4) 36.2 (8.5)
FC169 (III-7) 37 58.3 (18.6) 57.7 (18.4) 17.9 (1.0) 39.3 (0.4) 38.5 (12.1) 37.9 (10.1) 27.7 (2.6)
FC169 (III-8) 52 61.2 (13.4) 63.8 (17.1) 42.8 (1.5) 38.9 (2.4) 39.5 (26.5) 38.0 (17.1) NR
FC169 (III-12) 38 55.8 (17.8) 57.5 (16.7) 32.5 (1.1) 34.7 (0.5) 39.3 (7.6) 36.3 (7.8) NR
FC169 (IV-4) 14 56.9 (10.7) 58.6 (6.4) NR NR 39.2 (36.9) 37.3 (18.5) 33.7 (9.1)
FC188 (II-2) 43 52.3 (13.6) 58.1 (5.1) 40.7 (5.0) 48.6 (3.5) 29.5 (6.1) 39.3 (5.6) NR
46 46.7 (9.2) 58.3 (11.3) 40.7 (4.1) 45.1 (4.3) 25.0 (6.9) 40.9 (7.5) NR
49 49.1 (3.4) 22.4 (8.4) 38.4 (2.3) NR NR NR NR
Amplitudes of evoked responses are given in parentheses (for motor NCVs in mV and for sensory NCVs in mV).
Normal NCV values: motor median nerve =>50.5 m/s; ulnar nerve =>51.1 m/s; tibial nerve =>41.1 m/s; sensory median nerve =>39.3 m/s;
ulnar nerve = >37.5 m/s; sural nerve = >32.1 m/s.
Normal amplitude values: motor median nerve =>6 mV; ulnar nerve =>8 mV; tibial nerve =>6 mV; sensory median nerve =>8.8 mV; ulnar
nerve = >7.9 mV; sural nerve = >6.0 mV.
NR = not recordable.
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P < 0.001; r = 0.78, P = 0.005, respectively). In contrast, the
MCVs of median, ulnar and posterior tibial nerves did not
correlate with distal muscle strength in MFN2 patients (r =
0.50, P > 0.05; r = 0.48, P > 0.05; r = 0.58, P > 0.05, respec-
tively). These findings indicate that the weakness is the con-
sequence of axonal loss as reflected in the reduced
amplitudes in all motor nerves.
Mean median nerve TLIs in patients with MFN2 muta-
tions (0.30 6 0.06, range: 0.16–0.43) were not significantly
different from those of 158 healthy controls (0.31 6 0.04,
range: 0.23–0.43). TLIs in the majority of patients in each
group were distributed over a narrow range of values. In
both early and late-onset groups, TLIs displayed similar dis-
tributions (0.30 6 0.07, range: 0.22–0.43; 0.31 6 0.06, range:
0.16–0.39, respectively). This finding was expected in CMT2
and supports the hypothesis that axonopathy in patients with
MFN2 mutations is uniformly distributed along nerves.
Ophthalmological findings
Three patients (II-6 and III-1 in Family FC6, and II-3 in
Family FC1) developed bilateral optic atrophy during
the course of CMT. A patient (II-6 in Family FC6) showed
visual impairment at 10 years and experienced a subacute
deterioration of visual acuity as low as 20/130 bilaterally. Her
son (III-1 in Family FC6) experienced visual deterioration
from 13 years and subacute loss of visual acuity as low as 20/
100 bilaterally. However, the other patient (II-3 in Family
FC1) could not recall the exact age of visual impairment
onset and experienced a prolonged decline of visual acuity
to as low as 20/200 in the right eye and 20/400 in the left. A
central scotoma was detected in all of the above patients.
Also, these affected individuals had colour vision defects, and
their Ishihara colour plate test results were low (2/21–9/21).
Afferent pupillary defect was not found, and intraocular
pressures were not increased. Fundus examination of three
patients showed a white flat optic disc, attenuation of peri-
pupillary blood vessels and thinning of the retinal nerve fibre
layer. The macular, peripheral retina and blood vessels
appeared normal, as were the anterior segments of the
eye. In addition, one patient (III-1 in Family FC6) had
the cup of optic disc showing concentric enlargement and
an oval shape. Visual evoked potentials (VEPs) showed no
amplitudes in one patient, and markedly reduced amplitudes
and delayed patterns in the other patients (Fig. 4A and B).
Over the course of several years, both patients in the FC6
family experienced visual acuity recovery to near-normal
levels; however, another patient (II-3 in Family FC1) did
not improve.
Two daughters of an HMSN VI patient (II-3 in Family
FC1) did not have optic atrophy, but extremely severe axonal
CMT phenotypes were expressed in both. They showed nor-
mal visual acuity (20/20 in both sides) and VEP patterns.
Two families (FC55 and FC87) with R364W MFN2 muta-
tions (like FC1 and FC6) showed normal VEP patterns
without optic atrophy (Fig. 4C and D). In addition, two
families with R94W, previously reported for HMSN VI,
also displayed normal VEP patterns without optic atrophy
(Fig. 4E). Moreover, a patient (III-2 in Family FC34) with an
early onset with L92P, which showed a clinical course resem-
bling those of R364W or R94W mutations, did not have
optic atrophy and normal VEP findings (Fig. 4F). Retinitis
pigmentosa was not found in any study subject.
MRI findings
Twenty-one patients with MFN2 mutations were subjected
to brain MRI studies. Eight affected individuals from four
families had abnormal MRI findings, namely, T2 and FLAIR
high-signal intensities in centrum semiovale, periventricular
and subcortical white matters. The onset age of one patient
(II-2 in Family FC55) was earlier than 10 years; however,
those of the other seven patients were later. In eight affected
individuals, neither hypertension nor diabetes was found.
One patient (II-2 in Family FC55) had confluent periven-
tricular white matter high-signal lesions in right frontal lobe
for her age without any other explanation than CMT
(Fig. 5A). Moreover, follow-up T2-weighted MRI scans over
3 years showed no interval change (Fig. 5B). She was born at
full period, and no evidence of epileptic seizure, loss of con-
sciousness or behavioural disturbances was documented.
Two patients (III-4 and III-8 in Family FC169) had abnor-
mal brain MRI results in association with transient dysar-
thria and migraine. Patient III-4 in Family FC169 showed
a confluent lesion in the left parietal lobe and multiple
non-specific but definitely pathogenic hyperintensities for
age (Fig. 6A). She experienced repeated attacks of transient
dysarthria persisting for between a few hours and 2 days at
the longest. These symptoms recurred at irregular intervals.
The other patient (III-8 in Family FC169), the cousin of
FC169 (III-4), had similar symptoms. Both experienced
migraine without aura.
A patient (II-2 in Family FC188) experienced a sudden
attack of transient right upper limb and facial sensory loss for
1 month at 43 years, and, subsequently, experienced recur-
rent brief transient episodes of paraesthesia with a right
upper limb predominance. Brain MRI showed T1 low, T2
and FLAIR high-signal intensities in left subcortical lesion
without abnormal enhancement (Fig. 6B).
Three patients (III-12 in FC169, and II-5 and III-3 in
FC81) harbouring SNHL showed multiple subcortical
white matter lesions (Fig. 6C). One patient (II-3 in Family
FC48) with bilateral extensor plantar responses also dis-
played multiple non-specific but pathogenic subcortical
hyperintense lesions (Fig. 6D), but an MRI scan of the
whole spinal code showed no abnormalities.
Histopathological findings
Sural nerve biopsies were performed in seven patients (see
Table 2). On light microscopic examination, numbers of mye-
linated nerve fibres (MNFs) in the early onset group ranged
from 2327/mm2 to 2837/mm2 (Fig. 7A); however, numbers in
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the late- onset group ranged from 7821/mm2 to 8356/mm2
(Fig. 7B). Semi-thin transverse section of the sural nerve
showed a marked loss of large myelinated fibres in early
onset patients (Fig. 8A), but relatively greater preservation
in late-onset patient (Fig. 8B). In both groups, unmyelinated
nerve fibres were more preserved than large MNFs; however,
those were clustered and atrophied (Fig. 8A). These features
are compatible with axonopathy, which is characteristic in
CMT2. In one patient (II-3 in Family FC1), the mean number
of MNFs was 2299/mm2, and unmyelinated nerve fibres were
relatively better preserved than MNFs. In this patient, diverse
features, like pseudo-onion bulb formations that contained
more than one axon, were observed by electron microscopy
(Fig. 9A and B). One gastrocnemius muscle biopsy was avail-
able for histopathological study, in a patient (III-4 in Family
FC135) who carried the MFN2 mutation. This muscle biopsy
showed many small grouped atrophic foci, which is charac-
teristic of neurogenic muscle atrophy; however, no ragged-red
fibres (RRFs) were observed.
Discussion
In the present study, we identified 10 causative MFN2 mis-
sense mutations in 15 CMT families (24.2%). In particular,
→
→
→
→
→→
Fig. 4 Fundus examination and VEP in unusually severe patients with early age at onset. (A) FC1 (II-3) with R364W showed optic atrophy
and no bilateral VEP amplitudes. (B) FC6 (II-6) with R364W displayed a white, flat optic disc, and markedly decreased bilateral VEP
amplitudes. (C) FC55 (II-2) with R364W did not have optic atrophy and showed normal VEP findings. (D) FC87 (II-3) with R364W who also
did not have optic atrophy and showed normal VEP patterns. (E) FC113 (II-5) with R94W, previously reported for HMSN VI, also did not
have optic atrophy and displayed normal VEP findings. (F) FC34 (III-2) of early onset with L92P showed a very similar clinical course to those
with R364W or R94W mutations and had normal VEP findings without optic atrophy.
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Fig. 5 Transverse T2-weighted brain MRI showing a confluent hyperintense lesion in the right frontal lobe in Patient FC55 (II-2)
with an R364W MFN2 mutation. The abnormalities observed in T2-weighted sequences showed no interval change between
3 (A) and 6 years of age (B).
Fig. 6 Transverse FLAIR brain MRI images in patients with MFN2 mutations. (A) FC169 (III-4) with transient dysarthria and
migraine displayed multiple non-specific but definitely pathogenic subcortical hyperintense lesions. (B) FC188 (II-2) having a transient
right upper limb and facial sensory loss of 1 month’s duration showed T2 and FLAIR high-signal intensities without abnormal
enhancements. (C) FC81 (III-3) with H165R showed SNHL and displayed multiple subcortical white matter lesions that could
not be attributed to age. (D) FC169 (III-7) with R280H showed extensor plantar responses and also demonstrated a non-specific
but pathogenic hyperintense lesion.
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six of these mutations were determined to be novel. Muta-
tions observed in the present study involved regions highly
conserved between species, for example, Candida elegans and
Drosophila melanogaster (Fig. 1B). All of them cause amino
acid substitutions with different properties.
The phenotypic descriptions of the 15 families concur
with previous reports and suggest that MFN2 mutations
cause an axonal CMT2 phenotype (Zu¨chner et al., 2004;
Kijima et al., 2005; Lawson et al., 2005). In affected indivi-
duals with MFN2 mutations, phenotypes were clearly differ-
entiated into two subgroups. In the early onset group (<10
years), unusually severe phenotypes predominated, whereas
in the late-onset group (>10 years), most patients had mild
phenotypes. Moreover, phenotype severity was also concor-
dant among siblings in individual families, and the clinical
courses of families with the same mutations were very
similar, indicating that severe and mild phenotypes are
determined mainly by the position of mutations in the
MFN2 gene.
In semiological terms, all 12 cases with an early onset
required a walker or a wheelchair and were categorized as
severe by CMTNS. However, in the late-onset group, one
exhibited no disability and the others showed either difficulty
walking or an inability to run and were categorized as mild to
moderate by CMTNS. Moreover, our electrophysiological
findings showed a striking difference between the two sub-
groups (see Table 3). In the early onset group, CMAP ampli-
tudes were markedly reduced, to the extent that CMAPs were
not recordable in eight patients (67%). However, in the late-
onset group, nerve conductions were recordable in all
patients, and some patients presented nearly normal values.
In addition, follow-up studies showed that axonal degenera-
tion changes were more rapid in patients with an early onset.
Therefore, genetically determined phenotypes were found to
correspond well with electrophysiological findings.
It appears that mutational spots with high frequency
might exist in MFN2, at the 94th, 105th, 280th and 364th
codons. In particular, two different missense mutations at
the 94th codon have been reported in seven unrelated
CMT2A families (four cases of R94W and three cases of
R94Q), including two cases in the present study (Zu¨chner
et al., 2004, 2006; Kijima et al., 2005). T105M has been
detected in three families, once in the present study and
once by Zu¨chner et al. (2004) and Lawson et al. (2005);
R280H has also been detected in three families, once in
the present study and twice by Zu¨chner et al. (2004); whereas
R364W has been reported in five families, four unrelated
families in the present study and once by Zu¨chner et al.
(2006).
Population data on MFN2 mutations by ethnicity are
limited, because the relevance of the MFN2 mutation in
CMT2 was reported for the first only recently (Zu¨chner
et al., 2004). In the present study, we identified MFN2 muta-
tions in 24.2% of 62 axonal CMT2 families. Zu¨chner et al.
(2004) reported 7 (19.4%) mutations in 36 CMT2 families
representing several ethnic groups, a Japanese group
reported 7 (8.6%) mutations in 81 axonal or unclassified
CMT patients (Kijima et al., 2005) and an American
study reported 3 (23.1%) mutations in 13 CMT2 families
(Lawson et al., 2005). The mutation frequency observed by
the Japanese group was lower than those reported by other
studies, which may be due to sampling or analytical differ-
ences or to different genetic backgrounds. We screened
MFN2 mutations by directly sequencing all exons by PCR
in CMT2 patients, whereas Kijima et al. (2005) performed
denaturing high-performance liquid chromatography
(DHPLC) before sequence analysis, which might have
reduced the detection rate. In addition, Kijima et al.
(2005) has reported a case of de novo mutation among 7
Japanese CMT2A families with MFN2 mutations (14.4%);
Fig. 7 Light microscopic findings of sural nerve of Patient III-2 in Family FC34 with an early onset (A) and of Patient II-2 in Family
FC188 with a late onset (B). The number of large myelinated fibres was markedly reduced in early onset patient to 2327/mm2; however,
myelinated fibre numbers were relatively well preserved in late-onset patient to 8356/mm2. Toluidine blue stain. Magnification: A, ·400 and
B, ·400.
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however, we could prove de novo mutations in at least 5 out
of 15 CMT2A families in this study (33.3%). Although
additional evidence from other population studies is
necessary, we suggest that the frequency of de novomutations
may be higher. And, even though a combined analysis of
population-based studies on different ethnic groups is not
yet available, we believe that MFN2 mutations are the most
common mutation form in axonal CMT.
Electrophysiological evidence indicates that the predomi-
nant distal muscle weakness and atrophy of CMT is due to
the evolving length-dependent degeneration of motor axons
(Hattori et al., 2003). Distally accentuated muscle weakness
was found to be strongly correlated with a reduction in the
number of functioning large axons, as assessed by CMAPs,
but not with nerve conduction slowing. TLI is usually used
for determining differential motor conduction slowing
Fig. 9 Sural nerve biopsy of Patient II-3 from Family FC1 with an early onset. Semi-thin transverse section of the sural nerve showing diverse
features, such as pseudo-onion bulb formations that contained more than one axon (A and B) These features may be caused by Schwann
cell proliferation in clusters of regenerating nerve fibres. Magnification: A, ·10 400 and B, ·7080, Scale bar = 1 mm.
Fig. 8 Sural nerve biopsy of Patient III-2 from Family FC34 with an early onset (A) and of Patient II-2 in Family FC188 with a late onset (B).
(A) In electron microscopic findings of sural nerve, unmyelinated nerve fibres were relatively preserved and showed multiple clusters of
axonal regeneration (arrow) in early onset patient. (B) However, in this figure, large MNFs were more preserved in late-onset patient than
in early onset patient. Standard electron microscope techniques are used. Magnification: A, ·7080 and B, ·2500, Scale bar = 1 mm.
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between the distal and proximal segments of a nerve
(Dubourg et al., 2001). In the present study, median
nerve TLI was the same in controls and in patients with
MFN2 mutations. Moreover, median nerve TLI varied little
in controls, or in patients with either an early or late onset,
suggesting that axonal degeneration occurring in patients
with MFN2 mutations is homogeneous throughout a
given nerve.
Optic atrophy, when noted at the examination of an axo-
nal CMT patient with visual dysfunction, is demonstrated in
HMSN VI (Voo et al., 2003). We identified three HMSN VI
patients in two unrelated axonal CMT families with R364W
mutation. Before molecular diagnosis of MFN2 gene, all of
them were checked for mitochondrial mutations relevant to
Leber’s hereditary optic atrophy (MIM no. 535000); how-
ever, we could not find any mitochondrial mutations. In the
FC1 family, children with axonal CMT phenotype did not
have visual impairments. Another two families with R364W
did not have optic atrophy and two families with R94W,
previously reported for HMSN VI, also did not have visual
impairments (Zu¨chner et al., 2006). In addition, an early on-
set patient harbouring L92P mutation, with a clinical course
that resembled those with R364W or R94W mutations, did
not have optic atrophy. In fact, optic atrophy was only
demonstrated by extremely severe axonal CMT patients
with an early age at onset, and not by those with a late age
at onset. In addition, it has been reported that HMSN VI had
variant inherited patterns, and there has been reported an
evidence of incomplete penetrance of optic atrophy, whereas
the CMT phenotype was expressed in all mutation carriers
(Voo et al., 2003; Zu¨chner et al., 2006). Therefore, both the
incomplete penetrance and the appearance of optic atrophy
in unusually severe patients may be causes of reduced pene-
trance. On the basis of these findings, we suggest that axonal
CMT with optic atrophy harbouring MFN2 mutation might
be a variation of an early onset severe CMT2A phenotype.
The MRI findings of patients with MFN2 mutations are
interesting. We identified a high incidence of CNS involve-
ments in 8 of 21 patients (38%), by brain MRI. Comparing
our findings with those of a previous report, which found an
increased T2 signal in both cerebellar peduncles (Zu¨chner
et al., 2006), our MRI findings showed T2 and FLAIR high-
signal intensities in centrum semiovale, periventricular and
subcortical white matters without abnormal enhancement
(see Figs 5 and 6). In addition, confluent T2 hyperintensities
were detected in the periventricular white matter of frontal
and parietal lobes, and the white matter lesions were con-
sidered definitive pathological lesions that could not be
attributed to age. In a female patient (II-2 in Family
FC55), the abnormalities observed in T2-weighted sequences
showed no interval change between 3 and 6 years of age,
which differs from the findings of cerebral lesions in unusual
CMTX (CMT neuropathy type X) cases associated with tran-
sient CNS abnormalities, in which such changes are rever-
sible over a relatively short period (Paulson et al., 2002;
Hanemann et al., 2003). Subclinical CNS involvement in
patients with Cx32 mutations has been previously reported
(Nicholson et al., 1998; Bahr et al., 1999). We also found
subclinical CNS involvements in patients with MFN2 muta-
tions. In addition, abnormal MRI findings were more com-
mon in the late-onset group; therefore, we considered that
these were not necessarily associated with age at onset or
clinical severity. Moreover, it would be of interest to deter-
mine whether these non-specific but pathogenic findings are
also found frequently in other populations with MFN2
mutations.
However, the relation between these abnormal brain MRI
findings and mitochondrial dysfunction due to MFN2 muta-
tions has not been established. The possible explanation for
white matter changes in brain MRI findings of our patients is
that MFN2 is highly abundant in brain, and it has been well
known that mitochondria play a pivotal role in coordinating
programmed cell death; therefore, while numerous cell death
pathways are activated following an episode of brain ischae-
mia, mitochondrial dysfunction appears to be a crucial factor
in the life or death decision (Fiskum et al., 2000; Zipfel et al.,
2000; Bach et al., 2005; Korde et al., 2005). Whatever the exact
pathomechanism turns out to be, it is important to remember
that there are clinical examples of CNS involvements.
MFN2 mutations have been associated with clinical find-
ings suggesting CNS involvement. CMT with a pyramidal
feature is an axonal form of CMT with variable pyramidal
features but without frank spasticity (Vucic et al., 2003). In
the present study, extensor plantar responses were found in
one patient (II-3 in Family FC48) and brain and spine MRI
findings were normal; however, the other patient (III-7 in
Family FC169) with extensor plantar responses had an
abnormal brain MRI. Both of these patients had flexor plan-
tar weakness and increased knee and ankle reflexes but no
frank spasticity, which is differentiated from spastic paraple-
gia. These findings are similar to the previous report by Zhu
et al. (2005). In addition, SNHL was found in three patients
with H165R and M376T mutations; all three cases had multi-
ple subcortical hyperintense lesions on brain MRI. Although
the additional evidences from in vivo or in vitro studies are
necessary, we suggest that MFN2 mutations may cause vari-
able CNS involvements.
Nerve biopsy findings in CMT2A patients showed typical
evidence of axonopathy, such as axonal cluster formation,
atrophy and loss of thick MNFs, as is found in CMT2
(Berciano et al., 1986; Thomas et al., 1996). The mean num-
ber of myelinated fibres in patients with an early onset was
reduced by 70% compared with that in patients with a late
onset. However, unmyelinated nerve fibres were similarly
well preserved in both groups (see Figs 7 and 8). In a patient
(II-3 from Family FC1), an electron microscopic examina-
tion showed some pseudo-onion bulb formations (see Fig. 9),
and it would appear that this feature may have been caused
by Schwann cell proliferation in clusters of regenerating
nerve fibres.
Mutations in MFN2 gene are now viewed as the primary
cause of axonal autosomal dominant CMT2A, and, thus, it
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has been suggested that MFN2 should be screened for in
these patients. However, clinical and electrophysiological
phenotypes of CMT patients with MFN2 mutations were
significantly different in early and late disease-onset groups,
and optic atrophy was found only in CMT2 patients with
unusually severe phenotypes with an early age at onset. In
addition,MFN2 mutations show variable CNS involvements.
On the basis of prior evidence and the present study, it seems
probable that MFN2 mutations affect the nervous system at
various levels, and that HMSN VI might be a variant of an
early onset severe CMT2A phenotype.
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